Brokerage firm Janney Capital Upgrades its rating on BioDelivery Sciences International(NASDAQ:BDSI). The shares have been rated Buy. Previously, the analysts had a Neutral rating on the shares. The rating by Janney Capital was issued on Sep 23, 2016.
BioDelivery Sciences International (BDSI) made into the market gainers list on Tuesdays trading session with the shares advancing 4.04% or 0.11 points. Due to strong positive momentum, the stock ended at $2.83, which is also near the day’s high of $2.86. The stock began the session at $2.75 and the volume stood at 8,39,345 shares. The 52-week high of the shares is $7.04 and the 52 week low is $1.86. The company has a current market capitalization of $152 M and it has 5,36,39,979 shares in outstanding.
BioDelivery Sciences International(BDSI) last announced its earnings results on Aug 9, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $5.00M. Analysts had an estimated revenue of $3.35M. Earnings per share were $-0.31. Analysts had estimated an EPS of $-0.31.
Several Insider Transactions has been reported to the SEC. On Aug 12, 2016, William B Stone (director) sold 16,000 shares at $2.57 per share price.Also, On Mar 23, 2016, Charles Bramlage (director) purchased 8,850 shares at $2.82 per share price.On Mar 22, 2016, Niraj Vasisht (Chief Technology Officer) purchased 1,000 shares at $2.80 per share price, according to the Form-4 filing with the securities and exchange commission.
BioDelivery Sciences International Inc. is a specialty pharmaceutical company. The Company develops and commercializes either on its own or in partnerships with third parties applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology a small erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product ONSOLIS (fentanyl buccal soluble film) as well as its approved product BUNAVAIL (buprenorphine and naloxone buccal film) and its product candidate BELBUCA utilize its BEMA technology.